Yüklüyor......
Optimizing the use of biological therapy in patients with inflammatory bowel disease
Biological therapy revolutionized the treatment of inflammatory bowel disease (IBD) during the last decade. These monoclonal antibodies, which target tumor necrosis factor (TNF), integrins or IL12/23, have been approved—or are in development for—both Crohn’s disease (CD) and ulcerative colitis (UC)....
Kaydedildi:
| Yayımlandı: | Gastroenterol Rep (Oxf) |
|---|---|
| Yazar: | |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Oxford University Press
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4324872/ https://ncbi.nlm.nih.gov/pubmed/25567472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/gastro/gou087 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|